Safety Of Lu-177-Dotatate In Patients With Advanced Neuroendocrine Tumors: Data From A Us Expanded Access Program

M. Allen-Auerbach,E. Wolin,V. Nassiri,P. Broberg,G. El-Haddad

Journal of Clinical Oncology（2021）

引用 0|浏览20

暂无评分

摘要

4604Background: The NETTER-1 clinical trial showed that peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival in patients with somatostatin-receptor-p...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要